ACM
NTLA icon

Aster Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Aster Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-386
Closed -$2.74K – 1131
2026
Q1 		$2.74K Buy
+386
New +$4.92K ﹤0.01% 735
2025
Q2 		– Sell
-5,859
Closed -$59.1K – 1407
2025
Q1 		$59.1K Buy
5,859
+5,527
+1,665% +$55.8K 0.01% 775
2024
Q4 		$3.87K Buy
+332
New +$5.18K ﹤0.01% 896

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Aster Capital Management's NTLA Position: Q2 2026 in Review

Aster Capital Management sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 386 shares — an estimated $2.74K sold.

Aster Capital Management first reported a position in NTLA in Q4 2024 and held it in 3 quarters. The position peaked at $59.1K in Q1 2025. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Aster Capital Management reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Aster Capital Management sold 386 Intellia Therapeutics shares in Q2 2026, an estimated $2.74K.
  • Aster Capital Management first reported a position in Intellia Therapeutics in Q4 2024 and held it in 3 quarters.
  • Aster Capital Management's Intellia Therapeutics position peaked at $59.1K in Q1 2025.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.